A Potential Treatment of Congenital Sodium Diarrhea in Patients With Activating GUCY2C Mutations

Novel GUCY2C variant causing familial diarrhea in a Mennonite kindred and a potential therapeutic approach

(2021) Rachel M. Wolfe et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas

(2020) Hugo R. Jonge et al.   FEBS LETTERS

Intestinal Failure and Aberrant Lipid Metabolism in Patients With DGAT1 Deficiency

(2018) Jorik M. van Rijn et al.   GASTROENTEROLOGY

Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders

(2018) Scott A Waldman et al.   GUT

Selective inhibition of intestinal guanosine 3′,5′-cyclic monophosphate signaling by small-molecule protein kinase inhibitors

(2018) Marcel J. C. Bijvelds et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Congenital secretory diarrhoea caused by activating germline mutations inGUCY2C

(2015) Thomas Müller et al.   GUT

Reduced sodium/proton exchanger NHE3 activity causes congenital sodium diarrhea

(2015) Andreas R. Janecke et al.   HUMAN MOLECULAR GENETICS

Inhibition of Heat-Stable Toxin–Induced Intestinal Salt and Water Secretion by a Novel Class of Guanylyl Cyclase C Inhibitors

(2015) Marcel J. C. Bijvelds et al.   JOURNAL OF INFECTIOUS DISEASES

Familial Diarrhea Syndrome Caused by an ActivatingGUCY2CMutation

(2012) Torunn Fiskerstrand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: Application for treatment of diarrhea

(2008) A. Y. Kots et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA